The Indian drugmaker expects regulatory approval for its vaccine against Covid-19 by June. Efficacy readings from its last stage of clinical trials are expected in May.
Cadila is looking to hire contract manufacturers for additional 50-70 million doses of its vaccine, on top of 100 million that will come from its own capacity.
India’s private sector remains hesitant to invest in R&D. This is understandable, as the domestic market often fails to reward differentiated technologies adequately.
Speaking at ThePrint OTC Thursday, NSE CEO Ashishkumar Chauhan said the exchange has been trying to list itself since 2016, but it couldn’t happen due to one reason or the other.
Mechanical engineer & alumnus of IIM-A & IAS France, Kota was General Manager in HAL’s Light Combat Aircraft division. He was selected from a pool of eight candidates.
No nation other than China can negotiate one-on-one with Trump on an equal footing. That’s why the middle powers who so far formed the core of multilateral bodies now feel orphaned.
COMMENTS